| Entries |
| Document | Title | Date |
|---|
| 20080200548 | N-Acetylcysteine Amide (Nac Amide) for Treatment of Oxidative Stress Associated with Infertility - An in vitro culture and/or fertilization medium containing N-acetylcysteine amide (NAC amide) reduces or prevents oxidative stress and free radical formation that contribute to the cellular damage and eventual demise of sperm, oocytes and embryos that are cultured, fertilized and maintained in vitro. The NAC amide-containing medium composition for in vitro culture and fertilization is suitable for use in the culture of oocytes, in the culture and development of early embryos, in the preparation or culture of sperm, and in the pre-treatment of oocytes or sperm. The NAC amide-containing composition supports the growth of viable embryos until blastocyst stage. | 08-21-2008 |
| 20080262085 | Method For Restructuring Keratin Fibers - The invention relates to a method for restructuring keratin fibers during which a keratin fiber is brought into contact with cystine and with at least one dicarboxylic acid having 2 to 10 carbon atoms. The invention also relates to preparations for use in this method. | 10-23-2008 |
| 20080262086 | SUBSTITUTED ANTHRANILIC ACIDS - Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema associated with congestive heart failure, hepatic disease, renal disease including nephrotic syndrome, or clearance of toxic substances from the body. | 10-23-2008 |
| 20080287541 | Kit for Treatment of Cancer - The present invention relates to a kit for the treatment of cancer comprising (a) a container for containing a first compound (i) or a precursor thereof, said first compound or precursor being a compound that oxidizes glutathione (GSH); (b) a container for containing a second compound (ii) or a precursor thereof, said second compound or precursor being a compound that forms an adduct or conjugate with GSH; (c) a container for containing a third compound (iii) or a precursor thereof, said third compound or precursor being a compound that inhibits the rate-limiting enzyme of GSH biosynthesis, gamma-glutamylcysteine synthetase (GCS); and (d) a container for containing a fourth compound (iv) or a precursor thereof, said fourth compound or precursor being a compound that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR). | 11-20-2008 |
| 20080306158 | Methods to Prevent Cytotoxicity Using N-Acetyl-Cysteine - Compositions and methods to inhibit adverse physiological effects caused by resin-based and resin-containing materials are disclosed. More specifically, the use of N-acetyl-cysteine (NAC) to inhibit hydroxyethyl methacrylate (HEMA)-mediated cell death and cytotoxicity. | 12-11-2008 |
| 20080312326 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist - The present invention relates to the use of EP | 12-18-2008 |
| 20080319072 | COMPOSITION AND METHOD FOR TREATING BACTERIAL, VIRAL, FUNGAL DISEASES, INFLAMMATION AND PAIN - The present invention is directed to compositions and methods of treating bacterial, viral, fungal diseases; inflammation or inflammatory-related disorders; pain; and skin conditions. The composition comprises an organic solvent extract, which is prepared by the method comprising the steps of: (a) mixing methionine with water, (b) adding an aqueous hypochlorite solution to the methionine solution and mixing, (c) adding a water-immiscible organic solvent to (b) and mixing, and (d) separating the organic solvent phase from the water phase to obtain the organic solvent extract. The present invention is also directed to a method for preparing the organic solvent extract. | 12-25-2008 |
| 20090030079 | USES OF TRIENTINE AND PENICILLAMINE AS COUNTERMEASURES TO METAL CONTAMINATION - Methods are provided for the alleviation, prevention and treatment of negative effects of overexposure to metal contaminants. Subjects exposed to a metal contaminant can be treated using trientine and/or penicillamine or salts, esters, solvates thereof. In addition, communities can protect its members by securing sufficient quantities of such countermeasures. | 01-29-2009 |
| 20090036534 | Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction - A pharmaceutical composition and methods of producing and application of the composition for treating myocardial infarction of a subject are disclosed. The pharmaceutical composition comprises a therapeutically effective amount of at least one synthesized compound selected from the group consisting of SEC, SPC, SBC, SPEC, SAC, SAMC, and SPRC, and a pharmaceutically acceptable carrier. | 02-05-2009 |
| 20090048342 | Combination of Bioavailable Methionine With at Least One Essential Oil - The invention concerns a food composition, designed to complement animal feed in methionine, said composition having a synergistic bactericidal effect on the bacterial activity of the bowel flora. Said food composition of bioavailable methionine comprises: a) a bioavailable methionine compound and b) at least one essential oil. | 02-19-2009 |
| 20090069428 | CATALYTIC ANTIOXIDANTS AND METHODS OF USE - The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substrates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes. | 03-12-2009 |
| 20090149540 | Compositions and Methods for Attenuating Mitochondria-Mediated Cell Injury - The present invention relates to a S-nitrosated mitochondria-targeted thiol-based antioxidant prodrug and uses therefore for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. When activated, prodrug of the present invention can specifically provide a NO* donor and a thiol-based antioxidant to mitochondria thereby decreasing the degree of mitochondrial dysfunction. | 06-11-2009 |
| 20090192227 | N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease - The present invention relates to N-acetylcysteine compositions and methods for treating inflammation and redox imbalance in acute exacerbations of inflammatory lung disease. | 07-30-2009 |
| 20090209647 | NUTRITIONAL METHOD - A method of improving nutrition and/or treating low grade inflammation in an elderly human subject comprises administering to said subject a cysteine source so as to provide metabolically available cysteine in the diet of said subject in a proportion relative to all available amino acids which is greater that the proportion of cysteine relative to all amino acids which corresponds to the requirements of a healthy young human subject. | 08-20-2009 |
| 20090253793 | COMPOSITION AND METHOD FOR BINDING ACETALDEHYDE IN STOMACH - This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/or amino groups. The compound(s) are mixed with a non-toxic carrier that effects sustained release of said compound(s) in the gastrointestinal tract. These compositions are of benefit in particular to patients having atrophic gastritis or achlorhydric or low acid stomach. | 10-08-2009 |
| 20090275659 | Phenyl acetic acid derivatives as inflammation modulators - Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives. | 11-05-2009 |
| 20090306207 | Treatment of Drug-Resistant Proliferative Disorders - α,β-Unsaturated sulfones, sulfoxides and sulfonamides according to Formula I: | 12-10-2009 |
| 20090318556 | BIOMARKERS FOR DETECTING RADIATION EXPOSURE: METHODS AND USES THEREOF - Disclosed herein are biomarkers for determining gamma radiation exposure by an animal or human. The biomarkers include 3-hydroxy-2-methylbenzoic acid 3-O-sulfate, N-hexanoylglycine, β-thymidine, taurine, xanthine, xanthosine, 2′-deoxyuridine, 2′-deoxycytidine, 2′-deoxyxanthosine, or any salt, ion, or combination thereof. Also disclosed are methods for determining gamma radiation exposure by an animal or human, which include the step of measuring the amount of one or more biomarkers specific to gamma radiation in the biological fluid and correlating the amount of said biomarkers to the amount of gamma radiation exposure by the animal or human. Systems for determining gamma radiation exposure by an animal or human and methods of treating an animal or human for gamma radiation exposure are also disclosed. | 12-24-2009 |
| 20100048707 | Polymeric Reagents Comprising a Terminal Vinylic Group and Conjugates Formed Therefrom - The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided. | 02-25-2010 |
| 20100063149 | FOOD COMPOSITION FOR BINDING ACETALDEHYDE IN MOUTH AND IN DIGESTIVE TRACK, AND METHOD FOR THE PREPARATION OF THE COMPOSITION - The object of the invention comprises food compositions, to which one or more acetaldehyde-binding compounds are added. The purpose of the compositions is to reduce the amount of detrimental acetaldehyde in the area of the mouth, the pharynx, the oesophagus, the stomach, and the small and large intestines, and through this, to reduce the risk of developing cancers in these areas. | 03-11-2010 |
| 20100137440 | LYSINE RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH LYSINE RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH LYSINE RIBOSWITCHES - The lysine riboswitch is a target for antibiotics and other small molecule therapies. Compounds can be used to stimulate, active, inhibit and/or inactivate the lysine riboswitch. | 06-03-2010 |
| 20100137441 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS - Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione. | 06-03-2010 |
| 20100179220 | METHOD FOR THE TREATMENT OF TINNITUS - Acamprosate, a drug used in the treatment of alcoholism, is a safe and successful alternative for neurossensorial tinnitus' treatment. | 07-15-2010 |
| 20100204328 | Solution and Method to Reduce, Treat and/or Prevent Oxidative Stress and Cell Activation - The present invention concerns a solution and methods to reduce, treat and/or prevent oxidative stress and cell activation. According to the invention the solution gives rise to the following concentrations of constituents within a blood flow of 0.1-18 mM N-acetyl-cysteine, optionally of 0.01-0.21 mM vitamin C, optionally of 2-26 mM gluconic acid and optionally of 0.01-5 mM glutathione. According to the invention the methods comprises adding a solution according to the invention in an extracorporeal setting through the membrane by adding the solution to the dialysis fluid, or by infusion of a solution according to the invention, either by bolus injection, continuous injection or a combination thereof. | 08-12-2010 |
| 20100204329 | METHOD OF USING AND ESTABLISHING AN ABSORPTION RATE LEVEL AND A NEURON FIRING LEVEL - A method for modulating the homeostatic relationship between various amino acid neurotransmitters in the body. The method includes modulating the rate of neuron firing and modulating the rate of cellular absorption. | 08-12-2010 |
| 20100222429 | Enzymatic Methods and Enzymes - Provided are methods to identify modulators and in particular inhibitors of body malodour formation employing peptidase enzymes, the peptidase enzymes and corresponding nucleotide sequences, expression vectors, transfected host cells, methods of forming the peptidase enzymes and methods to prevent body malodour. | 09-02-2010 |
| 20100234461 | Compositions For Improved Oxidative Status In Companion - A food composition that is useful for increasing antioxidant levels in the body is provided having increased levels of sulfur-containing amino acids, such as methionine, cysteine, or mixtures thereof. Methods of using these compositions for increasing antioxidant levels in the body in mammals, especially in companion animals, are also provided. | 09-16-2010 |
| 20100240755 | THERAPEUTIC AND COSMETIC COMPOSITIONS FOR TREATMENT OF SKIN - The present invention is directed to a skin cream containing L-glutathione and methyl sulfone in combination with perfluorodecalin and various vitamins such as Vitamin D and C. The cream can be used to treat cancerous and precancerous diseases found in or on the skin. | 09-23-2010 |
| 20100240756 | COMPOUNDS FOR TREATING INFLAMMATION AND PAIN - The present invention is directed to a compound of 2-N halo-4-methylsulfonyl-butyric acid, such as 2-N chloro-4-methylsulfonyl-butyric acid, or a pharmaceutically acceptable salt or solvate thereof. The present invention is also directed to a pharmaceutical composition comprises the compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation or inflammatory-related disorders, bacterial infection, pain, or skin conditions, by administering 2-N halo-4-methylsulfonyl-butyric acid to a subject in need thereof. | 09-23-2010 |
| 20100311837 | METHOD FOR IMPROVING STORAGE STABILITY OF GLUTATHIONE - The invention provides a method of improving the preservation stability of glutathione in a solid composition containing glutathione and arginine. In particular, glutathione and arginine are made to be coexistent with an organic acid such as citric acid, tartaric acid, ascorbic acid, malic acid, malonic acid, succinic acid, fumaric acid, maleic acid and the like. The amount of the organic acid to coexistent with glutathione and arginine is generally 0.1-2 parts by weight relative to 1 part by weight of arginine. | 12-09-2010 |
| 20110009489 | COSMETIC COMPOSITION COMPRISING VITAMIN U AS ACTIVE INGREDIENT FOR HEALING WOUNDS AND REDUCING WRINKLES - The present invention relates to a cosmetic composition comprising vitamin U as an active ingredient, more precisely a cosmetic composition for improving the skin wrinkles that contains vitamin U as an active ingredient. The cosmetics containing the composition of the present invention demonstrate excellent wound healing and wrinkle improvement effects. | 01-13-2011 |
| 20110071224 | NOVEL GAMMA-SECRETASE INHIBITOR - It is intended to provide a novel compound that has an excellent γ-secretase inhibitory effect and specifically inhibits Aβ production. | 03-24-2011 |
| 20110077303 | INCREASING GLUTATHIONE LEVELS FOR THERAPY - The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of methods, including, for example, reducing deleterious effects of oxidative stress; treating and/or preventing diabetes; and/or increasing GSH levels. | 03-31-2011 |
| 20110086920 | Gamma Glutamylcysteine Treatment or Prevention of Oxidative Injury - The present invention concerns the γ-glutamylcysteine treatment to reduce oxidative damage caused by ischemia/reperfusion events such as pulmonary hypertension, transplant, cardiac bypass and other surgeries, and trauma. In specific embodiments, preservation methods and apparatuses for preserving tissue for transplantation purposes is provided. | 04-14-2011 |
| 20110112192 | VERFAHREN ZUR GERUCHSEXTINKTION - Use of a pharmaceutically acceptable oxidation or reduction agent for disulfide bridges containing organic compounds for the treatment of odor formation in humans due to the consumption of allium plants or allium plant stuffs. | 05-12-2011 |
| 20110112193 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS - There is provided compounds of formula (I), wherein ring A, D | 05-12-2011 |
| 20110136910 | METHOD FOR STABILIZATION OF S-NITROSOGLUTATHIONE AND COMPOSITION PREPARED BY THE SAME - The invention relates to pharmaceutical compositions having alkaline pH comprising S-nitrosoglutathione (GSNO) as active ingredient together with usual additives, optionally with one or more polysaccharide-type polymer(s). Another subject of the invention is a method for stabilizing a solution or non-solid composition containing GSNO wherein the pH of the solution or composition is adjusted to an alkaline value. | 06-09-2011 |
| 20110237671 | COSMETIC COMPOSITION COMPRISING VITAMIN U AS ACTIVE INGREDIENT FOR HEALING WOUNDS AND REDUCING WRINKLES - Disclosed is a method of using a composition comprising vitamin U as an active ingredient to heal skin wound and inhibit collagenase. The method includes the step of applying an effective amount of the composition on human skin. The vitamin U is included at a concentration of 0.00001-30.0% (w/w) by the total weight of the composition. | 09-29-2011 |
| 20110237672 | Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production - The invention deals with the use of cysteine, a cysteine precursor substance or a cysteine derivative or a cysteine-containing substance to increase the oxygen supply to the tissue by increasing the ventilatory activity and/or by increasing the production of the blood-forming hormone erythropoietin (EPO), especially for the treatment of aging-related or disease-related conditions associated with a decreased oxygen supply to the tissue, especially in elderly subjects, in the treatment of malignant diseases and in cardiorespiratory diseases. | 09-29-2011 |
| 20110245342 | 3,5,3'-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF - The invention regards the use of triiodothyronine sulfate, commonly named T | 10-06-2011 |
| 20110245343 | ANTI-WRINKLE AGENTS - Provided are anti-wrinkle agents having a novel scaffold that is suitable as components for external skin preparations such as cosmetics. The anti-wrinkle agents comprise compounds represented by general formula (1), stereoisomers thereof, or pharmacologically acceptable salts thereof. Said anti-wrinkle agents have excellent efficacy in improving wrinkles and sagging that are caused by skin aging with increased age or occur as a result of photoaging due to ultraviolet rays exposure. [In the formula, R | 10-06-2011 |
| 20110251279 | Composition of Amino Acids for Sublingual Applying for Enhanced Skin Integument Repigmentation in Vitiligo and Method of its Administration - The task of this invention is in use of composition containing natural metabolites—amino acids, and in method of its administration which make it possible to increase skin repigmentation through sulfurcontaining compounds rise and activation of endogenic metabolic reactions, and to get persistent normalization of melanogenesis thus improving skin integument and as a consequence patient's quality of life. | 10-13-2011 |
| 20110294888 | Use of Salts of Sulfur-Containing Compounds for Controlling Parasites - The invention relates to a method of controlling nematodes with salts of sulphur-containing compounds. | 12-01-2011 |
| 20120010290 | Methods of Treating an Overweight or Obese Subject - The invention herein generally relates to methods of treating a subject having an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the invention herein provides a method of treating a subject having overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject. | 01-12-2012 |
| 20120016029 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD | 01-19-2012 |
| 20120022161 | ACETYCYSTEINE COMPOSITIONS AND METHODS OF USE THEREOF - A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed. | 01-26-2012 |
| 20120029082 | NUTRITIONAL OR THERAPEUTIC COMPOSITIONS TO INCREASE BODILY GLUTATHIONE LEVELS - Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described. | 02-02-2012 |
| 20120035264 | Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response - Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response. | 02-09-2012 |
| 20120041066 | MEDICAL FOODS FOR THE TREATMENT OF DEVELOPMENTALLY-BASED NEUROPSYCHIATRIC DISORDERS VIA MODULATION OF BRAIN GLYCINE AND GLUTATHIONE PATHWAYS - Describe herein are medical foods, pharmaceutical compositions, methods of compounding them, and method of using them for the treatment of developmentally-based neuropsychiatric disorders including particularly autism, ADHD, and persistent developmental disorders. The medical foods and pharmaceutical compositions typically include a methylglycine compound or precursor compound and an acetylcysteine compound or precursor compound. These methylglycine and acetylcysteine compounds may be prepared for sustained release or delivery. In some variations, a method of treating a developmentally-based neuropsychiatric disorder includes first determining if a patient is at risk for such a disorder by examining either or both phenotypical and genotypical biomarkers. The biomarkers may be used to tailor the dose to be delivered by the medial food or pharmaceutical composition. | 02-16-2012 |
| 20120136058 | Method For Increasing The Solubility Of Methionine By Mineral Addition And Acid Treatment - The present invention relates to a method for enhancing the solubility of methionine. More particularly, the present invention relates to a method for increasing the solubility of methionine, in which mineral and sulfuric acid are added at an appropriate ratio to enhance the methionine solubility, thereby overcoming the problem of low solubility of methionine in water. | 05-31-2012 |
| 20120157534 | COMPOSITIONS AND METHODS OF TREATMENT FOR INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention in a preferred embodiment is a combination of 5-aminosalicylic acid or 4-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 06-21-2012 |
| 20120172447 | COMPOSITION COMPRISING VITAMIN U AS ACTIVE INGREDIENT FOR HEALING SKIN WOUND - Disclosed is a composition comprising vitamin U as an active ingredient, more precisely a composition for repairing the skin wound that contains vitamin U as an active ingredient. The composition demonstrates excellent wound healing and skin wound repairing effects. | 07-05-2012 |
| 20120196936 | Composition Comprising S-Allyl-L-Cysteine as Active Ingredient for Preventing or Treating Gastrointestinal Disorders - A composition including S-allyl-L-cysteine as an active ingredient and having an anti- | 08-02-2012 |
| 20120214873 | CYSTEINE FOR PHYSIOLOGICAL INJECTION - This application describes methods of making and using physiological cysteine solutions useful for reversing a neuromuscular blockade caused by a cysteine-reversible neuromuscular blockade agent, that overcomes problems of cysteine precipitation and dimerization. | 08-23-2012 |
| 20120232150 | PHTHALANILATE COMPOUNDS AND METHODS OF USE - The invention provides antimicrobial compounds and compositions, and methods of using them. The compounds and compositions include, for example, a compound of any one of Formulas I-X. The invention further provides methods of preparing the compounds, and useful intermediates for their preparation. The compounds can possess highly specific and selective activity, such as antibacterial activity and/or enzymatic inhibitory activity. Accordingly, the compounds and compositions can be used to treat bacterial infections, or to inhibit or kill bacteria, either in vitro or in vivo. | 09-13-2012 |
| 20120238627 | N-ACETYL-L-CYSTEINE FOR THE TREATMENT OF ENDOMETRIOSIS - The invention relates to a new prescription of NAC in the treatment of endometriosis and of indications associated with endometriosis, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in the treatment of endometriosis is proposed. In one embodiment of the present invention the prescribed treatment regimen may be used e.g. in order to control the frequency and the intensity of pain symptoms (dysmenorrhea, dyspareunia and acyclic chronic pelvic pain), to reduce the size of endometriotic lesions eventually up to their disappearance, to reduce recurrences after surgery and/or to improve fertility. Side effects of this treatment are virtually absent and, in particular, this treatment does not hinder pregnancy. | 09-20-2012 |
| 20120252894 | COMPOUNDS FOR ALLEVIATING PAIN AND STRESS IN FETUS AND NEWBORN - The invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improve the outflow of chloride from neurons thereby promoting the inhibitory actions of GABA and alleviating pain and stress of the fetus during delivery and the newborn. The invention also relates to a pharmaceutical composition for use in a method for alleviating pain and stress of the fetus during delivery and the newborn comprising a compound according to the invention and a pharmaceutically acceptable carrier. | 10-04-2012 |
| 20120295977 | Organosulfur prodrugs for the prevention and treatment of infectious diseases - A method for enhancing the overall beneficial immune system response in a host that works in conjunction with the host's natural immune system response to enhance the host's ability to eliminate infectious microbes while simultaneously suppressing the toxicity of the immune system response to the host. Allium related organosulfur compounds are disclosed which have a various antimicrobial immunomodulatory properties that work together with the host's immune system in the prevention and treatment of disease. Prophylactic and therapeutic treatment is provided by administering an allium related organosulfur compound such that a localized thiosulfinate is caused to be non-enzymatically formed in response to localized generation by activated immune system cells of reactive oxygen species such as hydrogen peroxide. Suitable allium related organosulfur compounds may be administered to the host in an efficient manner through the use of S-AllylMercapto-N-AcetylCysteine (SAMNAC) or similar prodrugs. | 11-22-2012 |
| 20120309832 | Acetylcysteine Composition and Uses Thereof - This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent. | 12-06-2012 |
| 20130041033 | COMPOSITION COMPRISING VITAMIN U AS ACTIVE INGREDIENT FOR HEALING SKIN WOUND - Disclosed is a composition comprising vitamin U as an active ingredient, more precisely a composition for repairing the skin wound that contains vitamin U as an active ingredient. The composition demonstrates excellent wound healing and skin wound repairing effects. | 02-14-2013 |
| 20130046021 | METHODS OF TREATING CARDIOMYOPATHY, SYSTOLIC CARDIAC DYSFUNCTION AND THE SYMPTOMS OF CONGESTIVE HEART FAILURE WITH PROBENECID - Described herein are inventions is directed to methods of treating a cardiac dysfunction and symptoms of cardiac dysfunction in a subject that includes administering an amount of probenecid effective to treat a symptom of cardiac dysfunction. The probenecid may be administered in at least one of an injection, orally, or transdermally. The amount of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved New York Heart Association (NYHA) classification, a lower diuretic dose requirement, a lower serum BNP levels, a normalization of serum sodium concentrations, and combinations thereof In an embodiment, probenecid is administered over a period of about 8 hours to about 24 hours. Probenecid may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years. Probenecid may be administered in an amount sufficient to treat the symptoms of cardiac dysfunction. | 02-21-2013 |
| 20130053444 | DP2 ANTAGONIST AND USES THEREOF - Described herein is the DP | 02-28-2013 |
| 20130065961 | MODULATION OF PHYSIOLOGICAL PROCESSES AND AGENTS USEFUL FOR SAME - The present invention relates generally to a method of modulating glutathione metabolism in the central nervous system of mammals and to agents for use therein. More particularly, the present invention relates to a method of up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursor molecules. The method of the present invention is particularly useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate central nervous system oxidation homeostasis including, but not limited to, schizophrenia. | 03-14-2013 |
| 20130079411 | METHOD FOR PREVENTING OR TREATING A DISEASE, DISORDER OR CONDITION INDUCED BY RETINA ISCHEMIA - The present invention provides a method for preventing or treating a disease, disorder or condition induced by retina ischemia, comprising administering to a subject in need thereof a S-allyl-L-cysteine in a therapeutically effective amount. | 03-28-2013 |
| 20130116322 | ALKENYL NAPHTHYLACETIC ACIDS - The invention is concerned with the compounds of formula (I): | 05-09-2013 |
| 20130116323 | METHODS OF IMPROVING OR PRESERVING LUNG FUNCTION IN A PATIENT WITH A PULMONARY DISORDER - The described invention provides methods for improving or preserving lung function in a patient suffering from a pulmonary disorder comprising an inflammatory component by administering to the patient a pharmaceutical composition comprising a therapeutic amount of N-acetylcysteine, a derivative of N-acetylcysteine, or a pharmaceutically acceptable salt of N-acetylcysteine, wherein the therapeutic amount is effective to improve or preserve the lung function in the patient. | 05-09-2013 |
| 20130143967 | Organosulfur compounds for the prevention and treatment of neurodegenerative diseases - S-allylmercapto-N-acetylcysteine and related compounds are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compounds include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia. | 06-06-2013 |
| 20130165515 | Organosulfur Compounds for the Prevention and Treatment of Neurodegenerative Diseases - Divalent salts of S-allylmercapto-N-acetylcysteine and related compositions are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compositions include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia. | 06-27-2013 |
| 20130165516 | Acetylcysteine Composition and Uses Thereof - This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent. | 06-27-2013 |
| 20130172418 | PHARMACEUTICAL COMPOSITION COMPRISING N-ACETYL-L-CYSTEINE OR ITS DERIVATIVES FOR TREATING ANXIETY DISORDER - The present disclosure relates to a composition for treating anxiety disorder, particularly to a pharmaceutical composition comprising N-acetyl-L-cysteine or its derivatives for treating anxiety disorder such as post traumatic stress disorder or phobia. In accordance with the present disclosure, N-acetyl-L-cysteine can block the renewal of fear memories for a sustained period of time when it was administered during or after an exposure therapy to treat post traumatic stress disorder or phobia. | 07-04-2013 |
| 20130237603 | Acetylcysteine Compositions and Methods of use Thereof - A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed. | 09-12-2013 |
| 20130245121 | INCREASING GLUTATHIONE LEVELS FOR THERAPY - The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of methods, including, for example, reducing deleterious effects of oxidative stress; treating and/or preventing diabetes; and/or increasing GSH levels. | 09-19-2013 |
| 20130296430 | COMPOSITIONS AND METHODS FOR TREATING AUTISM AND AUTISM SPECTRUM DISORDER - The described invention provides a method for treating a behavioral deficit, such as irritability and stereotypic/repetitive behaviors, in a subject with autism spectrum disorder by administering a composition comprising a therapeutic amount of N-acetylcysteine, a derivative of N-acetylcysteine, or a pharmaceutically acceptable salt of N-acetylcysteine. | 11-07-2013 |
| 20130317107 | Platelet-Based Methods to Detect and Monitor Treatment Benefits in Mucosal and Nervous Systems Diseases - The described invention provides methods for treating a disease, disorder or condition comprising an inflammatory component that includes a platelet dysfunction component and methods for monitoring therapeutic efficacy of a therapeutic regimen for managing a disease comprising an inflammatory component that includes platelet dysfunction. | 11-28-2013 |
| 20130331450 | CLASS II HMG-COA REDUCTASE INHIBITORS AND METHODS OF USE - Disclosed are compositions and methods for treating bacterial infections. | 12-12-2013 |
| 20140005268 | PHARMACEUTICAL COMPOSITION FOR TREATING OXIDATIVE STRESS-INDUCED PATHOLOGY AND USE THEREOF | 01-02-2014 |
| 20140011879 | SERUM MARKERS FOR IDENTIFICATION OF CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS - Tools for diagnosis and management of patients suspected of having or having been previously diagnosed with systemic sclerosis are based on the determination one or more of the markers described herein, specifically, the markers having the amino acid sequence of SEQ ID NOS: 1-62 and 66-76 in a sample from the subject. Specific marker ratios and subsets of markers and ratios identify a patient and further subclassify the patient. The information may be used prospectively to study the response of subclassified patients to existing or novel therapeutic strategies. | 01-09-2014 |
| 20140018423 | ANTIMICROBIAL AGENT COMPRISING A CYSTEINE COMPONENT COVALENTLY BOUND TO A SUBSTRATE IN PARTICULAR BY BINDING THROUGH AN S-S BRIDGE VIA A SPACER MOLECULE - The invention relates to an antimicrobial agent where a cysteine compound is covalently bound to a substrate, in particular by binding through an S—S bridge via a spacer molecule to the substrate. The spacer comprises a carbon chain, optionally interrupted by one or more heteroatoms, e.g. O, S, N, P and Si; the chain is optionally substituted with one or more alkyl groups, preferably lower alkyl groups with 1-5 carbon atoms, hydroxyl groups or alkoxy groups. Also, the invention refers to a substrate that is coated with the antimicrobial agent of the invention. The agent has excellent antimicrobial properties and can be used to coat surfaces and substrates of various devices, such as medical devices or devices used in food handling, in order to prevent or inhibit accumulation and/or growth and/or proliferation and/or the viability of microorganisms and/or formation of biofilm. | 01-16-2014 |
| 20140024715 | METHOD AND KIT FOR ADMIINISTERING GAMMA-GLUTAMYL-D-CYSTEINE FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE - The present invention provides a method for preventing blood-brain barrier reperfusion injury in a mammalian blood-brain barrier endothelial cell during reperfusion following ischemic stroke comprising administering an effective amount of a γ-glutamyl-D-cysteine antioxidant to the subject and a kit for doing the same. | 01-23-2014 |
| 20140024716 | Composition Comprising S-Allyl-L-Cysteine as Active Ingredient for Preventing or Treating Gastrointestinal Disorders - A composition including S-allyl-L-cysteine as an active ingredient and having an anti- | 01-23-2014 |
| 20140024717 | Process For The Preparation Of A Sulfated Derivative Of 3,5-Diiodo-O-[3-Iodophenyl]-L-Tyrosine - The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chloro-sulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives. | 01-23-2014 |
| 20140039055 | Topical Glutathione Formulations For Menopausal Skin - Topical compositions to address menopausal skin conditions include an effective amount of S-acyl glutathione derivative and a carrier. Methods for addressing menopausal skin conditions include applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C | 02-06-2014 |
| 20140073694 | CYSTAMINE ANALOGUES FOR THE TREATMENT OF PARKINSON'S DISEASE - The present invention relates to the use of cystamine analogues for the treatment of Parkinson's disease. The present invention also relates to the use of composition comprising cystamine analogues and cysteine. The present invention relates to a method for modifying the progression of Parkinson's disease comprising administering a therapeutically effective amount of at least one cystamine analogue or a pharmaceutically acceptable salt of a cystamine analogue to a patient in need thereof. | 03-13-2014 |
| 20140080910 | COMPOUNDS FOR THE TREATMENT OF AUTISM IN A BABY CHILD - The invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improve the outflow of chloride from neurons for use in the treatment of autism in a baby or a fetus in need thereof. | 03-20-2014 |
| 20140100283 | Method to Increase Absorption and Bioavailability of Oral Glutathione - An improved method for delivery of glutathione, a major intracellular antioxidant, by oral administration of S-acetyl-glutathione (SAG) is provided. The method is designed to raise the circulating blood levels of glutathione via the administration of an effective amount of SAG in a delayed release composition. | 04-10-2014 |
| 20140113969 | Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure - Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes. | 04-24-2014 |
| 20140121277 | USE OF METHIONINE SULFOXIMINE TO TREAT ACUTE LIVER FAILURE AND OTHER DISEASES CAUSED BY AN INFLAMMATORY CYTOKINE RESPONSE - Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response. | 05-01-2014 |
| 20140128469 | DEUTERATED N-BUTYL BUMETANIDE - The present invention provides a compound of Formula I: | 05-08-2014 |
| 20140128470 | Acetylcysteine Composition and Uses Thereof - This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent. | 05-08-2014 |
| 20140135396 | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide - The invention is directed to the treatment of patients at risk for liver damage due to the overingestion of acetaminophen by administering agents that increase hepatic levels of nitric oxide. | 05-15-2014 |
| 20140163104 | USES OF AND METHODS OF TREATMENT WITH CYSTATHIONINE - The present invention relates to uses of and methods of treatment with cystathionine. In one embodiment, cystathionine reduces the development of toxin-induced liver and/or kidney disease induced by homocystinuria and/or acute nephropathy. In one embodiment, a cystathionine synthesis inhibitor is administered to increase tumor cell apoptosis and/or increase the efficacy of chemo therapeutic treatment. More particularly, cystathionine can protect cells against toxin-induced cellular apoptosis and/or cystathionine synthesis inhibitors can increase neuroblastoma cell kill rates during chemotherapy. | 06-12-2014 |
| 20140194515 | Use of a Composition Comprising an Antacid, a Mucolytic and a Gelling Agent in the Treatment of Cold - The present invention is directed to a medicine to alleviate and cure colds by reducing acid content and stimulation of increased mucus production due to the fact that active components of the substance consist of acid stanching components like proton pumps stanches, histamine-2-receptor-antagonists, mucus stimulating components as acetylcysteine and alginic acid. This together creates an optimal healing environment in the respirator passages. | 07-10-2014 |
| 20140200275 | Method for Treating Skin Cancer - A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 07-17-2014 |
| 20140206765 | Acetylcysteine Compositions and Methods of use Thereof - A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed. | 07-24-2014 |
| 20140235717 | FOOD PRODUCTS, PREPARATION, AND THERAPEUTIC METHODS - A method is provided for the supplementation of milk, dairy products, meat products, and other food substances generally considered to be a major part of the Western diet, with substances capable of balancing the ratio of methionine and cysteine. Drug therapy with various carbamoyl thioesters or glutamate receptor antagonists can also be used, alone or in combination with dietary supplements and vitamins, to prevent or treat the pathology resulting from a Western diet. | 08-21-2014 |
| 20140256816 | Adamantyl Derivatives as Therapeutic Agents - The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis. | 09-11-2014 |
| 20140275257 | N-ACETYL CYSTEINE COMPOSITIONS IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - The described invention provides a method and kit for treating a lupus condition with N-acetyl-L-cysteine (NAC) compositions that improve lupus disease activity driven by a decrease in the activity of the mammalian target of rapamycin (mTOR). The compositions of the described invention is effective to: (1) reduce fatigue; (2) reduce cognitive/inattentive component of attention deficit and hyperactivity (ADHD) self-report scale (ASRS); (3) reduce inflammation, for example, as measured by the systemic lupus erythematosus disease activity index (SLEDAI), and the British Isles Lupus Assessment Group (BILAG) score; (4) modulate mitochondrial potential and (5) reduce T cell cycle dysfunction driven by a decrease in the activity of the mammalian target of rapamycin (mTOR) in patients suffering from systemic lupus erythematosus (SLE). | 09-18-2014 |
| 20140288177 | Increasing Glutathione Levels for Therapy - The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of methods, including, for example, reducing deleterious effects of oxidative stress; treating and/or preventing diabetes; and/or increasing GSH levels. | 09-25-2014 |
| 20140316005 | COMPOSITIONS FOR IMPROVED OXIDATIVE STATUS IN COMPANION ANIMALS - A food composition that is useful for increasing antioxidant levels in the body is provided having increased levels of sulfur-containing amino acids, such as methionine, cysteine, or mixtures thereof. Methods of using these compositions for increasing antioxidant levels in the body in mammals, especially in companion animals, are also provided. | 10-23-2014 |
| 20140316006 | PH-SENSITIVE COMPOUND, USE, COMPOSITION AND TREATMENT PROCESS USING SAME - The subject of the present invention is a compound of formula (I) below, the addition salts thereof, the dimer thereof and also the organic or inorganic acid salts thereof, the optical isomers thereof, the geometric isomers thereof, and the solvates thereof such as hydrates: (I) These compounds are sensitive to pH and of use for the treatment of keratin fibres, such as human keratin fibres and in particular the hair. | 10-23-2014 |
| 20140343149 | METHOD OF INHIBITING ANGIOGENESIS - A novel angiogenesis inhibitor, and a method for inhibiting angiogenesis are provided. Also provided are a prophylactic or therapeutic agent for a disease accompanied by angiogenesis, and a method for preventing or treating a disease accompanied by angiogenesis. The angiogenesis inhibitor contains L-carbocisteine or a pharmaceutically acceptable salt thereof as an active ingredient. | 11-20-2014 |
| 20150038584 | MATERIALS FOR DISINFECTION PRODUCED BY NON-THERMAL PLASMA - Aspects of the present subject matter are directed to a method comprising contacting an fluid, optionally containing an added organic material, with a non-thermal plasma to form a disinfection composition, wherein the disinfection composition is a liquid, and contacting a surface with the disinfection composition, wherein the surface is at least partially disinfected upon contact with the disinfection composition. Additional aspects of the present subject matter are directed to a method comprising forming a disinfection composition by contacting an organic material with a non-thermal plasma, wherein the disinfection composition is a liquid. A further aspect of the present subject matter is directed to a disinfection composition comprising an organic material contacted by a non-thermal plasma, wherein the disinfection composition is a liquid. | 02-05-2015 |
| 20150045434 | METHIONINE COMPOUND INTENDED FOR ANIMAL FEED - The present invention relates to a novel liquid methionine composition, originating from the mother liquor from crystallization of methionine produced by fermentation, comprising between 30 and 50% by weight of methionine and having a dry matter comprised between 20% and 75% by weight and characterized in that it also comprises less than 0.5% by weight of isoleucine and between 0.9% and 1.3% of N-acetyl-methionine. | 02-12-2015 |
| 20150080468 | COMPOSITION AND METHOD FOR PROCESSING AND DELIVERING BIOAVAILABLE METHIONINE ANALOGS, DERIVATIVES, AND PRECURSORS, THEREOF - Methionine products/additives are added to dairy cattle feeds to promote milk volume production and to enhance milk components. Unfortunately the methionine products/additives solidify/crystallize at about 54° F. (12° C.), making the products/additives difficult to dispense in a liquid storage and pumping system in cold conditions, thus requiring a time-consuming, expensive process using specialty equipment to de-crystallize the product. In one aspect this invention is an admixture that keeps the methionine products/additives temperature at a level that does not crystallize and thus, eliminates the expensive and time-consuming drawbacks to using methionine products in colder climates. | 03-19-2015 |
| 20150141513 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS AND NEUROLOGICAL DISEASES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological degenerative disorders and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of narcolepsy, shift work sleep disorder, and as an adjunct treatment for obstructive sleep apnea/hypopnea, hypersomnias, like idiopathic hypersomnia, Psychiatric/neurodegenerative disorders, ADHD, Psychiatric/neurodegenerative disorders, Depersonalization disorder, Cognitive enhancement, Fatigue, Post-chemotherapy cognitive impairment and weight loss. | 05-21-2015 |
| 20150290161 | INCREASING GLUTATHIONE LEVELS FOR THERAPY - The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of methods, including, for example, reducing deleterious effects of oxidative stress; treating and/or preventing diabetes; and/or increasing GSH levels. | 10-15-2015 |
| 20150313855 | EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE - Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described. | 11-05-2015 |
| 20150352067 | AGENT FOR ELEVATING NITRIC OXIDE CONCENTRATION - An agent for elevating nitric oxide (NO) concentration comprising glutathione or a salt thereof as an active ingredient; an agent for elevating NO concentration comprising glutathione or a salt thereof as an active ingredient for preventing or ameliorating a vascular endothelial malfunction-related symptom, or dilating blood vessels or promoting blood flow by elevating NO concentration; and a method for elevating NO concentration by ingesting glutathione or a salt thereof. | 12-10-2015 |
| 20160000727 | BETA CAROTENE PREPARATION - An aqueous emulsion for use in veterinary medicine which contains beta carotene and can be administered parenterally from a sterile multi-dose container contains acetylcysteine in an amount of between 1 and 8 wt.-% as a substance which stabilizes the emulsion and protects preservatives and beta carotene from being decomposed. The beta carotene-containing emulsion can additionally contain at least one antioxidant and at least one preservative. As the antioxidant, ascorbyl palmitate or alpha-tocopherol can be added. The emulsion can further contain a solubilizer, for example isopropyl myristate or Solutol® HS 15. | 01-07-2016 |
| 20160008305 | TREATMENT OF A DIASTOLIC CARDIAC DYSFUNCTION WITH A TRPV2 RECEPTOR AGONIST | 01-14-2016 |
| 20160068478 | NOVEL STAT3 INHIBITORS - The present disclosure provides pharmaceutical compositions comprising Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of use. | 03-10-2016 |
| 20160081958 | USE OF METHIONINE SULFOXIMINE TO TREAT DISEASES CAUSED BY AN INFLAMMATORY CYTOKINE RESPONSE - Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response. | 03-24-2016 |
| 20160102363 | METHODS AND COMPOSITIONS FOR PREDICTING THERAPEUTIC EFFICACY OF KINASE INHIBITORS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OR RELATED DISORDERS - The invention discloses a diagnostic method for predicting the therapeutic efficacy of a broad specificity kinase inhibitor in a subject with refractory cancer comprising determining the locus-specific DNA methylation profile of the subject, wherein the locus-specific DNA methylation profile predicts the therapeutic efficacy of a broad specificity kinase inhibitor for treatment of a subject with refractory cancer. | 04-14-2016 |
| 20160106693 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES - A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter. | 04-21-2016 |
| 20160113876 | SWALLOWABLE N-ACETYLCYSTEINE TABLETS - This invention relates to swallowable tablets containing at least 80% by weight of N-acetylcysteine (NAC) and at least one pharmaceutically acceptable excipient, in particular tablets in which the sulfurous odor is absent, characterized in that the said tablets are assembled using a granulate prepared by means of a process of dry granulating the active ingredient alone, with which the excipients are mixed before compression. | 04-28-2016 |
| 20160143871 | AGENT FOR ALLEVIATING SIDE EFFECTS IN CANCER CHEMOTHERAPY - Agents containing (A) cystine or a derivative thereof and (B) theanine, in combination, are useful for reducing side effects of cancer chemotherapy, can reduce various side effects of cancer chemotherapy, and can improve the treatment completion rate of cancer chemotherapy. | 05-26-2016 |
| 20160193167 | METHOD AND KIT FOR ADMINISTERING GAMMA-GLUTAMYL-D-CYSTEINE FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE | 07-07-2016 |
| 20160250334 | Acetylcysteine Compositions and Methods of use Thereof | 09-01-2016 |
